ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för eltanexor. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

27 träffar

Bibliografisk träff 2023-05-01

Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis.

Camilli S, Lockey R, Kolliputi N.

Cell Biochem Biophys · review; journal article · DOI 10.1007/s12013-023-01135-2

Bibliografisk träff 2023-02-13

XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.

Wang Z, Pan B, Yao Y, Qiu J, Zhang X, Wu X, Tang N.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2023.114402

Bibliografisk träff 2022-11-01

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.

Pianigiani G, Gagliardi A, Mezzasoma F, Rocchio F, Tini V, Bigerna B, Sportoletti P, Caruso S, Marra A, Peruzzi S, Petito E, Spinozzi G, Shacham S, Landesman Y, Quintarelli C, Gresele P, Locatelli F, Martelli MP, Falini B, Brunetti L.

Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2022007563

Bibliografisk träff 2022-09-26

Next-Generation SINE Compound KPT-8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD.

English KG, Reid AL, Samani A, Coulis GJF, Villalta SA, Walker CJ, Tamir S, Alexander MS.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines10102400

Bibliografisk träff 2022-08-31

Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide.

Otte K, Zhao K, Braun M, Neubauer A, Raifer H, Helmprobst F, Barrera FO, Nimsky C, Bartsch JW, Rusch T.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines10092145

Bibliografisk träff 2022-08-30

Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα-NF-κB p65 Complex.

Chen J, Song D, Xu Y, Wu L, Tang L, Su Y, Xie X, Zhao J, Xu J, Liu Q.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2022.896108

Bibliografisk träff 2022-08-03

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.

Lee S, Mohan S, Knupp J, Chamoun K, de Jonge A, Yang F, Baloglu E, Shah J, Kauffman MG, Shacham S, Bhatnagar B.

J Hematol Oncol · letter; clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i · DOI 10.1186/s13045-022-01319-y

Bibliografisk träff 2022-06-01

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway.

Liu S, Wang S, Gu R, Che N, Wang J, Cheng J, Yuan Z, Cheng Y, Liao Y.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2022.847605

Bibliografisk träff 2022-04-27

Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.

Nie D, Xiao X, Chen J, Xie S, Xiao J, Yang W, Liu H, Wang J, Ma L, Du Y, Huang K, Li Y.

Exp Cell Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yexcr.2022.113180

Bibliografisk träff 2022-03-31

Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.

Yu H, Wu S, Liu S, Li X, Gai Y, Lin H, Wang Y, Edwards H, Ge Y, Wang G.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.17274

Bibliografisk träff 2022-03-26

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.

Qu B, Xu Y, Lu Y, Zhuang W, Jin X, Shi Q, Yan S, Guo Y, Shen Z, Che J, Wu Y, Tong L, Dong X, Yang H.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114257

Bibliografisk träff 2021-11-30

A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.

Cornell RF, Baz R, Richter JR, Rossi A, Vogl DT, Chen C, Shustik C, Alvarez MJ, Shen Y, Unger TJ, Ben-Shahar O, Wang H, Baloglu E, Senapedis W, Ma X, Landesman Y, Bai X, Bader J, Xu H, Marshall T, Chang H, Walker CJ, Shah J, Shacham S, Kauffman MG, Hofmeister CC.

Am J Hematol · letter; clinical trial, phase i · DOI 10.1002/ajh.26420

Bibliografisk träff 2021-06-24

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.

Govaerts I, Prieto C, Vandersmissen C, Gielen O, Jacobs K, Provost S, Nittner D, Maertens J, Boeckx N, De Keersmaecker K, Segers H, Cools J.

J Hematol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13045-021-01114-1

Bibliografisk träff 2021-06-22

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.

Uddin MH, Li Y, Khan HY, Muqbil I, Aboukameel A, Sexton RE, Reddy S, Landesman Y, Kashyap T, Azmi AS, Heath EI.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22136676

Bibliografisk träff 2021-05-03

The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response.

Liao Y, Ke X, Deng T, Qin Q.

Front Microbiol · research-article; journal article · DOI 10.3389/fmicb.2021.675112

Bibliografisk träff 2021-03-19

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.

Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A.

Gastroenterology · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1053/j.gastro.2021.03.022

Bibliografisk träff 2021-01-15

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.

Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R.

J Hematol Oncol · research support, non-u.s. gov't; research-article; multicenter study; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1186/s13045-021-01032-2

Bibliografisk träff 2021-01-04

Targeting XPO1 enhances innate immune response and inhibits KSHV lytic replication during primary infection by nuclear stabilization of the p62 autophagy adaptor protein.

Meng W, Gao SJ.

Cell Death Dis · research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41419-020-03303-1

Bibliografisk träff 2020-08-21

The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia.

Verbeke D, Demeyer S, Prieto C, de Bock CE, De Bie J, Gielen O, Jacobs K, Mentens N, Verhoeven BM, Uyttebroeck A, Boeckx N, De Keersmaecker K, Maertens J, Segers H, Cools J.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-20-1315

Bibliografisk träff 2020-02-01

Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.

Fischer MA, Friedlander SY, Arrate MP, Chang H, Gorska AE, Fuller LD, Ramsey HE, Kashyap T, Argueta C, Debler S, Byrne M, Villaume MT, Shaver AC, Senapedis W, Landesman Y, Baloglu E, Shacham S, Savona MR.

Blood Adv · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2019000359

Bibliografisk träff 2019-09-28

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.

Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, Kim S, Philip PA, Azmi AS.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms20194826

Bibliografisk träff 2018-12-18

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.

Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-18-0959

Bibliografisk träff 2018-10-19

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.

Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.26239

Bibliografisk träff 2017-11-30

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.

Crochiere ML, Hannus S, Hansen K, Becker F, Baloglu E, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.22801

Bibliografisk träff 2016-10-25

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.

Vercruysse T, De Bie J, Neggers JE, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-16-1580

Bibliografisk träff 2016-05-23

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.

Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT.

Leukemia · research-article; journal article · DOI 10.1038/leu.2016.145

Bibliografisk träff 2016-05-20

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R.

Leukemia · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2016.136